Health Affairs March 4, 2025
Health Affairs’ Senior Deputy Editor Rob Lott interviews Jihye Han of Brigham and Women’s Hospital and Harvard University on her recent paper that takes a closer look at the regulatory treatments for first-in-class drugs and how those differ between the US and Europe.
FULL TRANSCRIPT
Note: This transcription has been generated by AI. Please excuse any errors that may be reflected below.
Rob Lott:
Hello, and welcome to A Health Odyssey. I’m your host, Rob Lott. It’s not always best to be first. When it comes to drug development, for example, there’s a lot more risk associated with developing so called first in class drugs compared to simply making small tweaks over the same kind of old drug. After all,...
Today's Sponsors
Today's Sponsor